Haisco Pharmaceutical Group has been granted a patent for a pharmaceutical formulation containing a compound of general formula (A) as an active ingredient, along with its stereoisomer, salt, or prodrug. The formulation excludes reducing sugars in auxiliary materials. GlobalData’s report on Haisco Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Haisco Pharmaceutical Group, Peptide nano-particle conjugates was a key innovation area identified from patents. Haisco Pharmaceutical Group's grant share as of May 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11974985B2) discloses a pharmaceutical formulation for treating diabetes. The formulation includes auxiliary materials and an active ingredient, which is a specific compound or its stereoisomer, salt, or prodrug. Notably, the formulation does not contain reducing sugars, making it suitable for diabetic patients. The patent claims various embodiments of the formulation, including solid formulations like tablets, with specific dosage ranges ranging from 0.10 mg to 50 mg per unit.
Moreover, the patent covers methods for administering the pharmaceutical formulation to treat diabetes, emphasizing oral administration and providing dosage options from 1-500 mg per dose. The formulation's composition, including the content of diluent, microcrystalline cellulose, and mannitol, is also detailed in the claims. Additionally, the patent specifies the possible substitutions and configurations of the compound of general formula (A), along with the acceptable salts for the active ingredient. The coating layer in the formulation is prepared without a plasticizer, ensuring the stability and efficacy of the medication. Overall, the patent provides a comprehensive overview of a novel pharmaceutical formulation for diabetes treatment, offering specific dosage options and composition details for effective administration and patient compliance.
To know more about GlobalData’s detailed insights on Haisco Pharmaceutical Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
